PRESS RELEASE

Kreissparkasse Biberach tenders 15.17% stake in Biotest AG into Tiancheng (Germany) Pharmaceutical Holdings AG's tender offer

Munich, 13 June 2017 - Tiancheng (Germany) Pharmaceutical Holdings AG, a company indirectly controlled by Creat Group Corporation, ("Bidder"), announced today that Kreissparkasse Biberach has tendered its stake of 15.17% of ordinary shares in Biotest AG ("Biotest"), which is indirectly held via special funds, into the Bidder's voluntary public takeover offer for all outstanding shares in Biotest launched on 18 May 2017.

Including the 50.61 % stake of ordinary shares in Biotest which OGEL GmbH, Biotest's majority shareholder, already tendered into the offer, the Bidder has now secured a total of 72.88% of Biotest ordinary shares.

The completion of the takeover offer will be subject to a minimum acceptance threshold of at least 75% of all Biotest ordinary shares as well as foreign investment control and merger control approvals.

Attractive Offer for Shareholders

In line with the recently published reasoned statement of Biotest's Management and Supervisory Board, Creat invites the remaining shareholders of both share classes to accept the offer, which offers shareholders an attractive premium on their current holdings.

Mr Wu Xu, CEO of Creat Group Corporation, said: "We believe our offer to be highly attractive for Biotest shareholders, a view shared by Biotest's Management and Supervisory Board. This is especially true in light of Biotest's difficult multi-year transition period and current operational and financial challenges, evidenced by a notably reduced near- and mid-term profit outlook by Biotest management. We invite shareholders of both share classes who have not yet tendered to accept the offer in line with the Biotest Management and Supervisory Boards' recommendation."

As outlined in the offer document, the Bidder offers Biotest shareholders EUR28.50 per Biotest ordinary share and EUR19.00 per Biotest preference share in cash. Biotest shareholders can still accept the takeover offer by tendering their shares to the Bidder. The acceptance period has started on 18 May and will end on 15 June 2017, 24:00 hrs (Frankfurt am Main local time)/18:00 hrs (New York local time).

The official offer document as well as a presentation summarizing the key points of the offer are available at http://www.tiancheng-germany-pharmaceutical-angebot.de. The joint reasoned statement of the Biotest Management Board and Supervisory Board can be found at http://www.biotest.com/de/en/investor_relations/takeover-offer.cfm.

About Creat Group Corporation

Creat Group Corporation (www.creatgroup.com) is a leading Chinese investment group founded in 1992 that has significant expertise in the plasma industry. It invests in healthcare and pharmaceuticals, manufacturing, energy, finance, and natural resources. The company is based in Beijing, China, with other offices in Hong Kong and Shanghai. Through its investment in China's largest listed blood products company Shanghai RAAS as well as the 2016 acquisition of UK-based plasma supplier and manufacturer of plasma-derived protein therapeutics Bio Products Laboratory, Creat is a significant investor in the global plasma market.

Important Notice

This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Biotest. The definite terms and conditions of the takeover offer, as well as further provisions concerning the takeover offer, have been published in the offer document following approval by the German Federal Financial Supervisory Authority. Investors and holders of shares in Biotest are strongly advised to read the offer document and all other relevant documents regarding the takeover offer, since they contain important information.
The takeover offer has been issued exclusively under the laws of the Federal Republic of Germany and certain applicable provisions of U.S. securities law. Any contract that is concluded on the basis of the takeover offer is exclusively governed by the laws of the Federal Republic of Germany and is to be interpreted in accordance with such laws.

Media Contact

Knut Engelmann
CNC - Communications & Network Consulting AG
T +49 69 506 037 570